TaiRx Inc is a Taiwan-based company mainly engaged in the development and research of new drugs. The Company primarily focus on the research and development of cancer treatment drugs and sepsis adjuvant therapy drugs. The Company's main products include CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, TRX-105 and others. CVM-1118 and Rexis are in clinical trials, and Zelnite drugs are sold to domestic medical institutions at all levels through distributors.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
14/09/26	NT$16.00	+22.61%	704,594
11/09/26	NT$13.05	+0.77%	141,514
10/09/26	NT$12.95	+2.37%	114,054
09/09/26	NT$12.65	0.00%	58,808
08/09/26	NT$12.65	+0.40%	38,005

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 14/09/2026			5-day change	1st Jan Change
16.00 ^TWD	+22.61%		+26.98%	-26.94%

08-11	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-15	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	1.79B 56.41M 48.88M 46.13M 41.85M 78.51M 5.41B 79.08M 551M 212M 2.74B 212M 207M 8.72B	P/E 2024	-20.5x	P/E 2025	-11x
Enterprise Value	1.46B 46.02M 39.88M 37.63M 34.14M 64.05M 4.41B 64.51M 449M 173M 2.24B 173M 169M 7.11B	EV / Sales 2024	286x	EV / Sales 2025	75.1x
Free-Float	100%	Yield 2024 *	-	Yield 2025	-

08-11	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-15	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
22/09/25	TaiRx, Inc.(TPEX:6580) dropped from S&P Global BMI Index	CI
14/08/25	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
11/04/25	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
23/09/24	TaiRx, Inc.(TPEX:6580) added to S&P Global BMI Index	CI
11/08/24	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
11/04/24	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
09/08/23	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
11/04/23	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
10/08/22	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	CI
13/04/22	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
09/08/21	Tairx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	CI

1 day	+22.61%
1 week	+26.98%
Current month	+24.03%
1 month	+22.61%
3 months	+10.34%
6 months	-4.19%
Current year	-26.94%

TaiRx, Inc. Stock

Stocks

6580

TW0006580004

Biotechnology & Medical Research

Valuation: TaiRx, Inc.

Chart: TaiRx, Inc.

Latest news: TaiRx, Inc.

Press Releases: TaiRx, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: TaiRx, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	12.3	16.25
1 month	12.2	16.25
Current year	11.95	23.45
1 year	11.95	31.8
3 years	11.95	44
5 years	11.95	89.5
10 years	11.95	89.5

Manager	Title	Age	Since
Yi Wen Chu IRC	Investor Relations Contact	-	-
Du Shieng Chien CEO	Chief Executive Officer	-	22/08/2011
Jackson Huang DFI	Director of Finance/CFO	-	05/10/2015

Director	Title	Age	Since
Du Shieng Chien CHM	Chairman	-	22/08/2011
Yi Wen Chu BRD	Director/Board Member	-	18/12/2013
Hsiu Hui Li BRD	Director/Board Member	-	22/08/2011

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TAIRX, INC.	+22.61%	+26.98%	-46.76%	-42.86%	56.41M
LONZA GROUP AG	+0.56%	-4.71%	-2.45%	+9.18%	45.63B
REVOLUTION MEDICINES, INC.	+0.66%	-2.34%	+340.62%	+530.14%	43.96B
IQVIA HOLDINGS INC.	+1.49%	-0.78%	+41.90%	+24.75%	43.73B
BEONE MEDICINES AG	+2.11%	-1.24%	+9.09%	+78.25%	40.23B
CELLTRION, INC.	+0.34%	-4.03%	+9.34%	+38.90%	31.86B
ASCENDIS PHARMA A/S	+0.53%	-2.08%	-	-	17.4B
MEDPACE HOLDINGS, INC.	+1.34%	+0.70%	+21.35%	+112.62%	16.62B
EUROFINS SCIENTIFIC SE	+2.07%	+0.78%	+13.07%	+30.91%	14.46B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.85%	-5.33%	+78.63%	+31.45%	13.04B
Average	+2.99%	+1.09%	+51.65%	+90.37%	26.7B
Weighted average by Cap.	+0.95%	-2.00%	+75.83%	+127.90%

	2024	2025
Net sales	8.22M 259K 224K 211K 192K 360K 24.78M 362K 2.53M 973K 12.57M 971K 950K 39.97M	27.88M 877K 760K 717K 650K 1.22M 84.02M 1.23M 8.56M 3.3M 42.62M 3.29M 3.22M 136M
Net income	-139M -4.37M -3.78M -3.57M -3.24M -6.08M -418M -6.12M -42.64M -16.43M -212M -16.4M -16.04M -675M	-221M -6.95M -6.03M -5.69M -5.16M -9.68M -667M -9.75M -67.91M -26.17M -338M -26.12M -25.54M -1.07B
Net Debt	-505M -15.88M -13.76M -12.98M -11.78M -22.09M -1.52B -22.25M -155M -59.75M -772M -59.63M -58.32M -2.45B	-330M -10.39M -9M -8.5M -7.71M -14.46M -996M -14.56M -101M -39.1M -505M -39.02M -38.16M -1.61B